PLACENTAL STEM CELLS DERIVE FROM POST-PARTUM MANMALIAN PLACENTA, AND USES AND METHODS OF TREATMENT USING SAID CELLS
The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
1 .- 82 . (canceled)
83 . A method of treating an individual who has amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of isolated human placental stem cells, wherein said placental stem cells are OCT-4 + and CD34 − , wherein OCT-4 is octamer binding protein 4 (POU5F).
84 . The method of claim 83 , wherein said placental stem cells are OCT-4 + , CD34 − , SSEA3 − and SSEA4 − .
85 . The method of claim 83 , wherein said placental stem cells are OCT-4 + and CD34 − , and additionally SH3 + or SH4 + .
86 . The method of claim 85 , wherein said isolated placental stem cells are SH3+ and SH4 + .
87 . The method of claim 86 , wherein said isolated human placental stem cells are SSEA3 − and SSEA4 − .
88 . The method of claim 83 , wherein said placental stem cells are OCT-4 + , CD34 − , CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 − , and SSEA4 − .